Genocea’s herpes vaccine hits the mark in Phase II

Damian Garde Genocea Biosciences' in-development vaccine for genital herpes met its goals in a Phase II trial, sending the biotech's shares soaring. FierceBiotech News

One of Takeda’s big cancer bets flops in a Phase III lymphoma trial

Damian Garde Alisertib, a jewel of Takeda's $ 8.8 billion acquisition of Millennium Pharmaceuticals back in 2008, failed to make the grade in a Phase III lymphoma trial, forcing ...

Novo Nordisk’s game-changing oral diabetes drug clears Phase II

Damian Garde Novo Nordisk's new oral diabetes drug measured up to its injected counterpart in a midstage study, promising results the company heralds as a milestone in the field. FierceBiotech ...

Esperion gets out from under the FDA and speeds toward Phase III

Damian Garde Ann Arbor, MI, biotech Esperion Therapeutics finally resolved the FDA snag standing in the way of its ambitious plans for a new cholesterol drug, clearing the company to ...

Tetraphase spikes on a Phase III success for lead antibiotic

John Carroll Shares of Tetraphase Pharmaceuticals spiked 15% Wednesday afternoon after the biotech said its lead antibiotic hit its primary endpoint in a head-to-head Phase III study, ...

Auspex’s Huntington’s drug hits the mark in Phase III

Damian Garde Auspex Pharmaceuticals' treatment for a movement disorder tied to Huntington's disease met its main goal in a late-stage study, the company said, clearing the way ...

Spark snags a ‘breakthrough’ tag for its Phase III gene therapy

Damian Garde Gene therapy startup Spark Therapeutics has picked up the FDA's coveted breakthrough-therapy designation for its lead candidate, a one-time treatment that promises ...

Novo Nordisk’s first foray into obesity comes through in Phase III

Damian Garde In new late-stage data, Novo Nordisk's inaugural obesity drug spurred statistically significant weight loss compared to placebo, bolstering the company's case as ...

Despite a mid-stage miss, Cytokinetics is taking its ALS drug toward Phase III

Damian Garde Earlier this year, Cytokinetics tanked as its lead prospect, a treatment for amyotrophic lateral sclerosis (ALS), missed its primary endpoint and a slew of secondary goals ...

Arrowhead tanks as its hep B treatment disappoints in Phase II

Damian Garde Arrowhead Research watched its shares nose-dive after a peek at Phase II data on its in-development treatment for hepatitis B revealed that the RNAi therapy isn't measuring ...

AstraZeneca’s new antibiotic comes through in Phase III

Damian Garde AstraZeneca's antibiotic combination treatment beat out standard meropenem in treating complicated infections, the company said, setting the table for a near-term shot ...

Chikungunya vaccine shows antibody response in Phase I trial

Emily Mullin Following recent outbreaks in the Pacific and Caribbean, chikungunya virus has made its way to the U.S.–and drug developers have taken note of its continued spread. FierceBiotech ...
Page 2 of 1112345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS